ArticleFrontiers in oncology2026
Case Report: An interesting case of vision and hearing loss revealing CNS recurrence in Philadelphia-positive acute lymphoblastic leukemia.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Central nervous system (CNS) relapse in acute lymphoblastic leukemia (ALL) may occur despite systemic remission and can present with isolated neuro-ophthalmologic symptoms. Early diagnosis may be challenging as the initial neuroimaging and ophthalmologic evaluation can be non-diagnostic. Case presentation/discussion: We report on a 57-year-old man with Philadelphia chromosome-positive ( Conclusion: This case highlights delayed recognition of CNS relapse due to initial diagnostic anchoring and underscores the limitations of early imaging in detecting CNS involvement. CSF analysis remains the most sensitive diagnostic modality and should be pursued early in patients with ALL who present with unexplained visual or neurologic symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.